PT2448968T - ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL - Google Patents

ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Info

Publication number
PT2448968T
PT2448968T PT107397010T PT10739701T PT2448968T PT 2448968 T PT2448968 T PT 2448968T PT 107397010 T PT107397010 T PT 107397010T PT 10739701 T PT10739701 T PT 10739701T PT 2448968 T PT2448968 T PT 2448968T
Authority
PT
Portugal
Prior art keywords
alzheimer
oligomers
therapeutic
disease
diagnostic methods
Prior art date
Application number
PT107397010T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of PT2448968T publication Critical patent/PT2448968T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT107397010T 2009-06-29 2010-06-29 ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL PT2448968T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29

Publications (1)

Publication Number Publication Date
PT2448968T true PT2448968T (pt) 2021-04-30

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107397010T PT2448968T (pt) 2009-06-29 2010-06-29 ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
RU2555526C2 (ru) 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
RS61717B1 (sr) 2014-07-10 2021-05-31 Bioarctic Ab Poboljšana antitela koja vezuju a-beta protofibril
JP2018522891A (ja) 2015-07-21 2018-08-16 バイオアークティック アーベー 凝集ペプチドを標的とする外傷性脳損傷の治療方法
WO2018011353A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
CN112805031A (zh) 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer
US20250163135A1 (en) 2021-07-09 2025-05-22 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 p-タウ181レベルを使用した治療方法
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ES2235926T3 (es) * 1999-08-04 2005-07-16 The University Of Southern California Ensamblaje globular de proteina beta amiloide y sus usos.
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PL1737891T3 (pl) * 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
KR101581733B1 (ko) * 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
LT2282758T (lt) * 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams

Also Published As

Publication number Publication date
US20120100129A1 (en) 2012-04-26
PL2448968T3 (pl) 2021-09-13
ES2864049T3 (es) 2021-10-13
EP2448968B1 (en) 2021-01-27
JP2017197531A (ja) 2017-11-02
DK2448968T3 (da) 2021-04-12
CA2765602A1 (en) 2011-01-06
JP6884025B2 (ja) 2021-06-09
AU2010267640A1 (en) 2012-01-19
LT2448968T (lt) 2021-05-10
SMT202100237T1 (it) 2021-05-07
CA2765602C (en) 2021-05-25
EP3892633A1 (en) 2021-10-13
CY1124034T1 (el) 2022-05-27
JP2019218362A (ja) 2019-12-26
WO2011001366A1 (en) 2011-01-06
JP2012532094A (ja) 2012-12-13
HRP20210611T1 (hr) 2021-05-28
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
EP2448968A1 (en) 2012-05-09
SI2448968T1 (sl) 2021-07-30
HUE053949T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
PT2448968T (pt) ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
SI2282758T1 (sl) Protitelesa in vakcine za uporabo pri terapevtskih in diagnostičnih metodah za alfa-sinuklein-povezane motnje
ZA201107862B (en) Intrauterine system for use in medical treatment
PL2393399T3 (pl) Materac przeznaczony do użytku w domach opieki i szpitalach
LT2539366T (lt) Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose
LT2758433T (lt) Alzheimerio ligos tau-sąlygojamos patologijos terapija ir diagnostika baltymų pagrindu
ZA201107085B (en) Indolizine derivative and use thereof for medical purposes
IL220684A (en) Anaphylactic therapy for Alzheimer's and the aging brain
EP2182978A4 (en) TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
EP2386239A4 (en) IN VIVO IMAGING SYSTEM OF THE SUBJECT AND IN VIVO INTRODUCTION DEVICE IN THE FIELD
PT2405928T (pt) Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PL2410922T3 (pl) Urządzenie do przeprowadzania procedur diagnostycznych i/lub terapeutycznych
GB201121597D0 (en) Polyurethane oligomers for use in restorative dentistry
GB0918392D0 (en) Diagnostic and therapeutic methods
ZA201106056B (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
PT2470066E (pt) Método não invasivo para avaliação da perfusão de tecidos num doente
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
GB0912665D0 (en) Force-transmitting element for use in medical catheters
GB0905970D0 (en) Depsipeptides and their therapeutic use
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
SI2459721T1 (sl) Izboljšan humani dolgi pentraksin 3 ekspresijski sistem in njegove uporabe
IL219256A0 (en) System and method for noninvasive tissue examination
GB0909894D0 (en) Methods and preparations for curing multiple organ dysfunction in clinically ill patients
GB0910048D0 (en) Methods and preparations for curing multiple organ dysfunction in clinically ill patients
GB201008106D0 (en) Cell protective peptides for treating diseases and disorders associated with tissue damage